
Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
BSLN | Switzerland | CHF | Delayed | |
BSLNz | BATS Europe | CHF | Delayed |
Basilea Pharmaceutica AG engages in the discovering, developing, and commercializing drugs for bacterial or fungal infections. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis. It also develops Fosmanogepix, an antifungal drug for the treatment of Candidemia, which is in Phase II clinical trials; BAL2062 for invasive mold infections, which is in Phase I of clinical trials; and BAL2420, an antibiotics to treat severe Enterobacteriaceae infections. In addition, the company provides Zevtera, an antibiotic for the treatment of pneumonia, as well as develop for the treatment of Staphylococcus aureus bacteremia, acute bacterial skin, and skin structure infections. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.
Name | Age | Since | Title |
---|---|---|---|
Nicole Onetto | 72 | 2017 | Independent Non-Executive Director |
Alf Gunnar Martin Nicklasson | 70 | 2013 | Independent Non-Executive Director |
Thomas M. Werner | 69 | 2011 | Independent Vice-Chairman |
Leonard Kruimer | 67 | 2022 | Independent Non-Executive Director |
Carole A. Sable | 63 | 2023 | Independent Non-Executive Director |
Stephan Schindler | - | 2025 | Chairman |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review